ALLO – allogene therapeutics, inc. (US:NASDAQ)

DELAYED
$ usd
Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low
VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close
1D
5D
1M
3M
YTD
1Y
3Y
1 Day ALLO SPY QQQ SPX
Date
Time
Symbol
Company Name
Action
%Chg
5/13/2024
04:01 pm
allo
allogene therapeutics, inc.
BEAT
2.1%
3/14/2024
04:05 pm
allo
allogene therapeutics, inc.
MISS
1.3%
11/2/2023
04:02 pm
allo
allogene therapeutics, inc.
BEAT
16.7%
8/2/2023
04:02 pm
allo
allogene therapeutics, inc.
BEAT
9.6%
Earnings are essential to understanding the financial health of a company listed on any Stock Exchange. But what are Earnings, how are they calculated, when are they announced, and how are they used to make sound investment decisions?
The answers are right here.
Stock Stats
News Stats
All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings
Order Stats
Sub-Penny
Odd Lot
Avg. bid-ask spread
Avg. bid / ask size
Shares at ask / bid
Off exchange
Top News Gainers
2/6 Allogene Therapeutics Announces February and March 2020 Investor Conference Schedule 6.8%
3/18 Form 4 Allogene Therapeutics, For: Mar 16 Filed by: Chang David D 6.8%
3/17 Allogene Therapeutics Inc (NASDAQ: ALLO) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 6.7%
4/23 Form DEF 14A Allogene Therapeutics, For: Dec 31 5.9%
4/28 Form 4 Allogene Therapeutics, For: Apr 24 Filed by: Chang David D 5.9%
4/17 Allogene Therapeutics Inc (NASDAQ: ALLO) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. 5.5%
8/7 Allogene Therapeutics, Inc. (ALLO) CEO David Chang on Q2 2019 Results - Earnings Call Transcript [Seeking Alpha] 5.0%
3/24 MaxCyte and Allogene Therapeutics Sign Clinical and Commercial License Agreement to Enable the Advancement of Allogeneic CAR T (AlloCAR T™) Therapies 4.9%
3/13 Allogene Therapeutics Inc (NASDAQ: ALLO) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $35.00 price target on the stock. 4.7%
2/24 Form 4 Allogene Therapeutics, For: Feb 20 Filed by: SCHMIDT ERIC THOMAS 4.4%
Top News Decliners
3/12 Allogene Therapeutics Inc (NASDAQ: ALLO) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -15.8%
11/6 Allogene Therapeutics Inc (NASDAQ: ALLO) had its "hold" rating re-affirmed by analysts at JPMorgan Chase & Co.. They now have a $29.00 price target on the stock. -6.4%
8/11 Allogene Therapeutics Inc (NASDAQ: ALLO) had its "hold" rating re-affirmed by analysts at JPMorgan Chase & Co.. They now have a $29.00 price target on the stock. -5.4%
8/12 Allogene Therapeutics Inc (NASDAQ: ALLO) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -5.2%
3/20 Senator Richard Burr Sold a Fortune in Stocks While Playing Down Coronavirus Threat [The New York Times] -5.1%
11/12 Allogene Moves Forward With CAR-T Therapy Pipeline [Seeking Alpha] -5.1%
4/1 Allogene Therapeutics Announces Participation in Two Upcoming Virtual Investor Conferences -4.9%
9/25 Form 4 Allogene Therapeutics, For: Sep 23 Filed by: Kazam Joshua A -4.8%
5/22 Allogene Therapeutics Inc (NASDAQ: ALLO) is now covered by analysts at Stifel Nicolaus. They set a "hold" rating on the stock. -4.8%
11/5 Q3/2019 9/30/2019 EPS -0.500 ZacksConsensus -0.540 ActVsEst 0.040 - Beat -4.4%

Don’t Miss Out On The Next BIG Stock Move

Thanks for submitting the form.
ALLO – allogene therapeutics, inc. (US:NASDAQ)
DELAYED
$ usd
1D
5D
1M
3M
YTD
1Y
3Y
Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low
VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close
ALLO
SPY
QQQ
SPX
ALLO – allogene therapeutics, inc. (US:NASDAQ)
DELAYED
$ usd
1D
5D
1M
3M
YTD
1Y
3Y
Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low
VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close
ALLO SPY QQQ SPX
Stock Stats
All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings
Sub-Penny
Odd Lot
Avg. bid-ask spread
Avg. bid / ask size
Shares at ask / bid
Off exchange
Stock Stats
Order Stats
Sub-Penny
Odd Lot
Avg. bid-ask spread
Avg. bid / ask size
Shares at ask / bid
Off exchange
News Stats
All News
News Wires
Media Monitoring
SEC Edgar Filings
Upgrades
Downgrades
Initiated
Reiterated
Last Earnings
Last Earnings EPS
Next Earnings
News
5/16
08:14 am
allo
Low
Allogene Therapeutics, Inc. (NASDAQ: ALLO) had its price target lowered by analysts at HC Wainwright from $10.00 to $9.00. They now have a "buy" rating on the stock.
5/15
03:20 pm
allo
Low
Allogene Therapeutics, Inc. (NASDAQ: ALLO) had its "buy" rating re-affirmed by analysts at Truist Financial Co.. They now have a $17.00 price target on the stock.
5/14
03:01 pm
allo
Low
Allogene (ALLO) Q1 Earnings in Line With Estimates, Sales Lag [Yahoo! Finance]
5/14
08:07 am
allo
Low
Allogene Therapeutics, Inc. (NASDAQ: ALLO) had its price target raised by analysts at Stifel Nicolaus from $4.40 to $4.60. They now have a "hold" rating on the stock.
5/13
04:47 pm
allo
Low
Allogene Therapeutics Announces Pricing of $110 million Offering of Common Stock
5/13
04:11 pm
allo
Low
Allogene Therapeutics Reports First Quarter 2024 Financial Results and Business Update [Yahoo! Finance]
5/13
04:01 pm
allo
Low
Allogene Therapeutics Reports First Quarter 2024 Financial Results and Business Update
5/6
08:30 am
allo
Medium
Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update
4/26
08:41 am
allo
Low
Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma [Yahoo! Finance]
5/13/2024
04:01 pm
allo
2.1%
BEAT
3/14/2024
04:05 pm
allo
1.3%
MISS
11/2/2023
04:02 pm
allo
16.7%
BEAT
8/2/2023
04:02 pm
allo
9.6%
BEAT
Earnings are essential to understanding the financial health of a company listed on any Stock Exchange. But what are Earnings, how are they calculated, when are they announced, and how are they used to make sound investment decisions? The answers are right here.
5/14
06:51 am
Maintains
Hold
Hold
Stifel
Low
-3.0%
3/19
08:08 am
Reiterates
Buy
Buy
HC Wainwright
Medium
5.0%
3/18
02:57 pm
Reiterates
Outperform
Outperform
Royal Bank of Canada
Low
-2.8%
3/18
02:57 pm
Reiterates
Outperform
Outperform
Royal Bank of Canada
Low
-2.8%
3/15
12:17 pm
Reiterates
Outperform
Outperform
RBC Capital
0.0%
3/15
12:17 pm
Reiterates
Outperform
Outperform
RBC Capital
0.0%
2/27
01:17 pm
Maintains
Overweight
Overweight
JP Morgan
Low
0.3%
5/14
04:41 pm
allo
Medium
Form 8-K Allogene Therapeutics, For: May 13
5/14
04:38 pm
allo
Low
Form 424B5 Allogene Therapeutics,
5/13
04:04 pm
allo
Low
Form 10-Q Allogene Therapeutics, For: Mar 31
5/13
04:02 pm
allo
Low
Form 8-K Allogene Therapeutics, For: May 13
4/26
06:07 am
allo
Low
Form EFFECT Allogene Therapeutics,
4/24
04:19 pm
allo
Medium
Form 4 Allogene Therapeutics, For: Apr 22 Filed by: MOORE TIMOTHY L.
4/23
04:34 pm
allo
Medium
Form ARS Allogene Therapeutics, For: Dec 31
4/23
04:33 pm
allo
Medium
Form DEFA14A Allogene Therapeutics,
4/23
04:33 pm
allo
Medium
Form DEF 14A Allogene Therapeutics, For: Jun 05
Show more
Top News Gainers
2/6 Allogene Therapeutics Announces February and March 2020 Investor Conference Schedule 6.8%
3/18 Form 4 Allogene Therapeutics, For: Mar 16 Filed by: Chang David D 6.8%
3/17 Allogene Therapeutics Inc (NASDAQ: ALLO) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 6.7%
4/23 Form DEF 14A Allogene Therapeutics, For: Dec 31 5.9%
4/28 Form 4 Allogene Therapeutics, For: Apr 24 Filed by: Chang David D 5.9%
4/17 Allogene Therapeutics Inc (NASDAQ: ALLO) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. 5.5%
8/7 Allogene Therapeutics, Inc. (ALLO) CEO David Chang on Q2 2019 Results - Earnings Call Transcript [Seeking Alpha] 5.0%
3/24 MaxCyte and Allogene Therapeutics Sign Clinical and Commercial License Agreement to Enable the Advancement of Allogeneic CAR T (AlloCAR T™) Therapies 4.9%
3/13 Allogene Therapeutics Inc (NASDAQ: ALLO) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $35.00 price target on the stock. 4.7%
2/24 Form 4 Allogene Therapeutics, For: Feb 20 Filed by: SCHMIDT ERIC THOMAS 4.4%
Top News Decliners
3/12 Allogene Therapeutics Inc (NASDAQ: ALLO) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -15.8%
11/6 Allogene Therapeutics Inc (NASDAQ: ALLO) had its "hold" rating re-affirmed by analysts at JPMorgan Chase & Co.. They now have a $29.00 price target on the stock. -6.4%
8/11 Allogene Therapeutics Inc (NASDAQ: ALLO) had its "hold" rating re-affirmed by analysts at JPMorgan Chase & Co.. They now have a $29.00 price target on the stock. -5.4%
8/12 Allogene Therapeutics Inc (NASDAQ: ALLO) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -5.2%
3/20 Senator Richard Burr Sold a Fortune in Stocks While Playing Down Coronavirus Threat [The New York Times] -5.1%
11/12 Allogene Moves Forward With CAR-T Therapy Pipeline [Seeking Alpha] -5.1%
4/1 Allogene Therapeutics Announces Participation in Two Upcoming Virtual Investor Conferences -4.9%
9/25 Form 4 Allogene Therapeutics, For: Sep 23 Filed by: Kazam Joshua A -4.8%
5/22 Allogene Therapeutics Inc (NASDAQ: ALLO) is now covered by analysts at Stifel Nicolaus. They set a "hold" rating on the stock. -4.8%
11/5 Q3/2019 9/30/2019 EPS -0.500 ZacksConsensus -0.540 ActVsEst 0.040 - Beat -4.4%